AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tg Therapeutics's 15min chart triggers KDJ Golden Cross, bullish Marubozu signal.
ByAinvest
Thursday, Aug 28, 2025 3:02 pm ET1min read
Tg Therapeutics's 15-minute chart has recently triggered a Golden Cross on the KDJ indicator, accompanied by a Bullish Marubozu formation on August 28, 2025 at 15:00. This signifies a shift in momentum towards the upside, with the potential for further price appreciation. The current market dynamics are characterized by strong buying interest, which is likely to sustain the bullish momentum in the near future.
On August 28, 2025, at 15:00, TG Therapeutics Inc (TGTX) stock experienced a significant technical shift. The 15-minute chart triggered a Golden Cross on the KDJ indicator, accompanied by a Bullish Marubozu formation. This combination of signals signifies a shift in momentum towards the upside, indicating potential for further price appreciation [1].The Golden Cross occurs when a short-term moving average crosses above a long-term moving average, typically signaling a buy signal. The Bullish Marubozu formation, characterized by a single candlestick with no wicks, suggests strong buying pressure, further reinforcing the bullish sentiment [2].
The current market dynamics are characterized by strong buying interest, which is likely to sustain the bullish momentum in the near future. This positive technical development comes amidst recent earnings reports that showed mixed performance, with analysts adjusting their ratings accordingly. Goldman Sachs, for instance, has resumed coverage of TGTX with a Neutral rating and a $37.00 price target [3].
Investors should monitor the stock closely for further price movements. While the recent signals are promising, it is essential to consider the broader market conditions and the company's fundamentals. TG Therapeutics Inc focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases, with a strong pipeline of investigational medicines [4].
References:
[1] https://www.investing.com/equities/tg-therapeutics-inc
[2] https://www.investing.com/equities/tg-therapeutics-inc
[3] https://www.investing.com/equities/tg-therapeutics-inc
[4] https://www.investing.com/equities/tg-therapeutics-inc
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet